- Earth Science Tech has made meaningful progress over the last few years, building a business anchored in a conglomerate model, infrastructure as a service, and end-to-end vertical integration
- The company is focused on the seamless integration of patient care through its operating businesses that offer telemedicine and telehealth infrastructure for consultations and third-party providers, compounding services, and fulfilment
- ETST has leveraged vertical integration to not only support the operations of its businesses but also tap into both B2B and B2C segments for revenue and growth
Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, began the current fiscal year 2027 in a position of real financial strength, according to CEO and Board Chairman Giorgio R. Saumat letter to shareholders (https://ibn.fm/NC6CW). This position is the result of meaningful progress over the last several years, which built a business that is not only durable, self-sustaining, and positioned for long-term growth but also anchored in a conglomerate model, infrastructure as a service, and end-to-end vertical integration.
The company’s core value proposition is the seamless integration of patient care, from consultation (through telemedicine and telehealth platforms) and clinical support to compounding pharmacy operations and direct-to-patient fulfillment. The company provides this value through its operating businesses, which are strategically and vertically integrated: RxCompoundStore.com LLC (“RxCS”), Mister Meds LLC, Zoolzy LLC, Meduvo LLC, Peaks Curative LLC (“Peaks”), DOConsultation.com LLC (“DOC”), Las Vilas Health Care, Avenvi LLC, and MagneChef.
RxCS is a Miami-based licensed pharmacy that compounds sterile and non-sterile medication, while Mister Meds is an Abilene-based pharmacy that compounds sterile drugs and is licensed to handle hazardous drugs. Meduvo is Earth Science Tech’s recently acquired La Verne-based compounding pharmacy that makes and dispenses non-sterile medication. Combined, these compounding pharmacies are licensed in 34 jurisdictions in the United States (https://ibn.fm/Kw23s).
Earth Science Tech recently completed the acquisition of Zoolzy, a Doral-based wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products (https://ibn.fm/hHh5K). The acquisition taps into a new vertical and enables the company’s compounding pharmacies to secure essential raw materials at competitive wholesale prices, thus supporting ETST’s strategy to vertically integrate its operations end-to-end.
The vertical integration strategy is also evident in the operations of other subsidiaries, including Peaks and DOC. Peaks is a telemedicine referral platform that offers asynchronous consultation for compounded drugs, while DOC is a telehealth brand through which a team of medical experts offers virtual consultations and treatments, with prescriptions fulfilled by ETST’s compounding pharmacies.
Besides supporting vertical integration, the company’s telehealth and telemedicine platforms and compounding pharmacies serve a second purpose: they ensure that ETST not only sells products to consumers but also provides medical consultation tech infrastructure and compounding services to third-party providers and companies. As a result, ETST generates high-margin B2B revenue to supplement B2C revenue from consumers.
Earth Science Tech continues to leverage its conglomerate model, infrastructure-as-a-service, and vertical integration as well as optimized operational frameworks to drive growth and support scalable, sustainable expansion. And as Mr. Saumat stated in his letter, management expects “every company under the ETST umbrella to expand its geographic footprint this year” and that the company “will pursue acquisitions and/or partnerships where they help us meet that goal.”
For more information, visit the company’s website at www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
